SCHEMBL21753292

SCHEMBL21753292

Cc1cc(-c2ccncc2)ccc1CCl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QDPR P09417 1/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 1/20 0.41
KIF11 P52732 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PRMT6 Q96LA8 1/20 0.38
CYP3A4 P08684 3/20 0.37
PRKCI P41743 1/20 0.37
CYP2D6 P10635 1/20 0.37
AAK1 Q2M2I8 1/20 0.37
MAPK14 Q16539 1/20 0.37
P2RX7 Q99572 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
DYRK1A Q13627 1/20 0.36
CYP17A1 P05093 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753414 0.81 PRKCI (0.49) QDPRMAPTLMNAKIF11SMN1; SMN2
SCHEMBL11565504 0.81 SMN1; SMN2 (0.41) MAPTLMNASMN1; SMN2RAB9A
SCHEMBL21770153 0.80 MKNK1 (0.52) KIF11MEN1PRMT6CYP3A4DYRK1A
SCHEMBL21753283 0.80 MMP13 (0.41) MAPK14CYP19A1CYP11B1CYP11B2
SCHEMBL2272131 0.79 RXRA (0.50) MAPTLMNAKIF11
SCHEMBL1911837 0.76 NPC1 (0.58) QDPRMAPTLMNAKIF11SMN1; SMN2
SCHEMBL1138598 0.75 QDPR (0.39) QDPRMAPTLMNAKIF11SMN1; SMN2
SCHEMBL21753236 0.73 NPC1 (0.44) MAPTLMNANPC1RAB9AMEN1
SCHEMBL21770160 0.71 MKNK1 (0.44) PDE3BPDE3ACYP11B2
SCHEMBL21770161 0.71 LOXL2 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-15 US disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed
WO-2020039027-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS ASCENEURON S. A. (CH) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP QDPR 406/4885MAPT 22/4885LMNA 1742/4885
US-20210213005-A1 PYRROLIDINE GLYCOSIDASE INHIBITORS PREP, GAA, DNPEP QDPR 434/4885MAPT 24/4885LMNA 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.